

Head and Neck Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Clinical Research Manager:
Mehir Tharani

Clinical Research Coordinators:
Bao-An Huynh
Natalie Arechiga
Erin Palmer-Torrison

Data Coordinators:
Anastasiia Reipolska



■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Neo-adjuvant HNSCC

UCI 22-132

De-escalated Radiation for HPV 16+ Squamous Cell Carcinoma of the Oropharynx
 Coord: E. Palmer-Torrison
 Accrual: 17/111

UCI 23-190

Observation vs IP Adjuvant
 Coord: E. Palmer-Torrison
 Accrual: 0/5

1st Line Recurrent/Metastatic HNSCC

UCI 23-106

Pembro + Danvatirsen vs Pembro in 1st line Recurrent/Metastatic HNSCC
 Coord: N. Arechiga
 Accrual: 0/5

Alliance A092105

Ipi/Nivo +/- Cabozantinib
 Recurrent NPC
 Coord: B. Huynh
 Accrual: 0/5

Recurrent/Metastatic Salivary Gland Cancer

ETCTN 10553

Darolutamide + Leuprolide Acetate in Hormone Naïve AR+ Salivary Gland Cancer
 Coord: B. Huynh
 Accrual: 0/5



Broad Phase 1 Trials

UCI 22-87
(RMC-6236)

Mechanism: TKI
 Coordinator: Oliver
 Quines
 Accrual: 6/20

UCI 21-40
(Locally Advanced or Metastatic Solid Tumors)

DF6002 as a Monotherapy
 and in Combination w/ nivo
 Valerin
 CRC: B. Huynh
 Accrual: 4/6
Waitlist only

UCI 22-221
BiTe of B7-H6

(Central B7-H6 testing)
 HCC and Pancreatic
 (also NSCLC, HNSCC,
 CRC, and gastric)

Coord: P. Yang
 Accrual: 1/12
Waitlist only

UCI 22-156
PI: Parajuli
Mechanism:
Coordinator: J. Miranda
Accrual: 0/5
TIL

UCI 23-148
CJRB-01 (oral) +
Pembrolizumab

Mechanism: Live
 biotherapeutic product
 containing a novel strain
 belonging in the species
Leuconostoc
mesenteroides (*L.*
mesenteroides +
Pembrolizumab
 Coord: TBD
 Accrual: 0/6